Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells

Blood Cancer Journal

Volumn 3, Issue 6, 2013, Pages

  Chiron, D ^a,b,c   Maiga S ^a,b,c   Surget, S ^a,b,c   Descamps, G ^a,b,c   Gomez Bougie, P ^a,b,c,d   Traore, S ^e   Robillard, N ^d   Moreau, P ^b,d   Le Gouill, S ^a,b,c,d   Bataille, R ^a,c,e   Amiot, M ^a,b,c   Pellat Deceunynck, C ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CNRS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e UMR INSERM U892 CNRS 6299   (France)

Author keywords

AKT; C KIT; Growth factors; IGF1R; Multiple myeloma; Self renewal

Indexed keywords

CD45 ANTIGEN; IMATINIB; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; STEM CELL FACTOR; WORTMANNIN;

ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CELL RENEWAL; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84880864511     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.18     Document Type: Article

References (35)

1. Chiron D, Surget S, Maiga S, Bataille R, Moreau P, Le Gouill S et al. The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol 2012; 156: 679-683.
2. Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45 low/- CD38 high/ CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 2012; 26: 2530-2537.
3. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 1991; 78: 1996-2004.
4. Collette M, Descamps G, Pellat-Deceunynck C, Bataille R, Amiot M. Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. Eur Cytokine Netw 2007; 18: 120-126. (Pubitemid 47573420)
5. Menoret E, Maiga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M et al. IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol 2008; 181: 6837-6842.
6. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy Jr JD, Barlogie B et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009; 113: 4614-4626.
7. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005; 90: 706-707. (Pubitemid 40780900)
8. Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2008; 32: 379-382. (Pubitemid 351295923)
9. Chng WJ, Gualberto A, Fonseca R. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia 2006; 20: 174-176.
10. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028. (Pubitemid 44395016)
11. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26: 2737-2744.
12. Schmidt-Hieber M, Perez-Andres M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC et al. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 2011; 96: 328-332.
13. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutierrez N, San Miguel JF. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol 2003; 123: 858-868. (Pubitemid 37533298)
14. Descamps G, Pellat-Deceunynck C, Szpak Y, Bataille R, Robillard N, Amiot M. The magnitude of Akt/phosphatidylinositol 30-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol 2004; 173: 4953-4959. (Pubitemid 39387777)
15. Chiron D, Maiga S, Descamps G, Moreau P, Le Gouill S, Marionneau S et al. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis 2012; 48: 247-253.
16. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 96: 574-582.
17. Descamps G, Wuilleme-Toumi S, Trichet V, Venot C, Debussche L, Hercend T et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 2006; 177: 4218-4223. (Pubitemid 44359958)
18. Kulas DT, Freund GG, Mooney RA. The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling. J Biol Chem 1996; 271: 755-760. (Pubitemid 26034924)
19. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000; 59(Suppl 1): i21-i27.
20. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95: 56-61. (Pubitemid 30017224)
21. Montero JC, Lopez-Perez R, San Miguel JF, Pandiella A. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica 2008; 93: 851-859. (Pubitemid 351821721)
22. Steinbrunn T, Stuhmer T, Gattenlohner S, Rosenwald A, Mottok A, Unzicker C et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 2011; 117: 1998-2004.
23. Mahindra A, Cirstea D, Raje N. Novel therapeutic targets for multiple myeloma. Future Oncol 2010; 6: 407-418.
24. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
25. Paiva B, Perez-Andres M, Vidriales MB, Almeida J, de las Heras N, Mateos MV et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia 2011; 25: 697-706.
26. Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655-1665. (Pubitemid 28275024)
27. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009; 69: 3241-3244.
28. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 2010; 95: 415-423.
29. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654-3663. (Pubitemid 24175556)
30. Moreau P, Cavallo F, Leleu X, Hulin C, Amiot M, Descamps G et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 2011; 25: 872-874.
31. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
32. Bataille R, Robillard N, Pellat-Deceunynck C, Amiot M. A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev 2003; 194: 105-111. (Pubitemid 36886432)
33. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma 2006; 47: 39-42. (Pubitemid 43101722)
34. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomibinduced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009; 100: 366-369.
35. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 2012; 120: 3260-3270.